Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06721286

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma (ICC) With High Risk of Recurrence, Phase II, Single-center, Randomized Controlled Trial

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Intrahepatic Cholangiocarcinoma (Icc)

Interventions Gemcitabine + Cisplatin Surgery Teripalimab

Updated 1 time since 2025 Last updated: Dec 3, 2024 Started: Nov 12, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06721286, this PHASE2 trial focuses on Intrahepatic Cholangiocarcinoma (Icc) and remains actively recruiting participants. Sponsored by Tianjin Medical University Cancer Institute and Hospital, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Cancer Institute and Hospital

Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China